ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus price target of $5.10 for the company and are anticipating that the company will post ($0.17) EPS for the current quarter, according to Zacks. Zacks has also given ESSA Pharma an industry rank of 120 out of 265 based on the ratings given to its competitors.

Several research firms have issued reports on EPIX. Bloom Burton restated a “buy” rating on shares of ESSA Pharma in a research report on Thursday, May 18th. Zacks Investment Research downgraded ESSA Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, May 18th. ValuEngine downgraded ESSA Pharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 7th. Finally, Dawson James restated a “buy” rating on shares of ESSA Pharma in a research report on Thursday, August 3rd.

ILLEGAL ACTIVITY NOTICE: “ESSA Pharma Inc. (EPIX) Given Average Rating of “” by Brokerages” was published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/08/essa-pharma-inc-epix-given-average-rating-of-by-brokerages.html.

ESSA Pharma (NASDAQ EPIX) traded up 13.1475% during trading on Tuesday, reaching $0.3451. The company’s stock had a trading volume of 80,934 shares. ESSA Pharma has a 12 month low of $0.25 and a 12 month high of $3.59. The company’s market cap is $10.04 million. The stock’s 50 day moving average is $0.46 and its 200 day moving average is $1.73.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.